Privia Health Group (NASDAQ:PRVA) Announces Earnings Results

Privia Health Group (NASDAQ:PRVA) announced its earnings results on Thursday. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12, FiscalAI reports. Privia Health Group had a net margin of 1.19% and a return on equity of 3.52%. The business had revenue of $656.96 million during the quarter, compared to analyst estimates of $610.72 million. During the same period in the previous year, the business earned $0.29 EPS. The company’s quarterly revenue was up 13.2% compared to the same quarter last year.

Here are the key takeaways from Privia Health Group’s conference call:

• Privia raised its 2026 outlook above the high end of initial guidance across key financial metrics. At the guidance midpoints, adjusted EBITDA is expected to grow 23.9%, practice collections 13.1%, and care margin 16.3% year over year.
• Strong execution drove 12.2% growth in implemented providers and 19.2% growth in attributed lives year over year through the first nine months; adjusted EBITDA rose 21.9% to $114.7 million. Management cited operating leverage, with EBITDA reaching 28.8% of care margin.
• Privia agreed to acquire American Choice Healthcare’s MSSP ACO for about $36 million in cash. The ACO is expected to bring more than 36,000 attributed lives across 10 existing and three new states beginning in 2027, with minimal impact on 2026 results and a positive contribution to 2027 lives and adjusted EBITDA.
• The company expects free-cash-flow conversion of roughly 70%–75% of adjusted EBITDA, citing taxes and the timing of MSSP-related payments; it had previously guided to 70%–80%. Privia ended Q3 with $446.3 million in cash and no debt, and expects at least $520 million at year-end.

Privia Health Group Stock Up 2.0%

Shares of PRVA traded up $0.48 during mid-day trading on Friday, hitting $24.42. 2,807,727 shares of the company traded hands, compared to its average volume of 1,143,537. The company has a market capitalization of $3.12 billion, a PE ratio of 93.93 and a beta of 0.76. Privia Health Group has a 1-year low of $18.92 and a 1-year high of $28.82. The business has a 50 day moving average of $21.04 and a 200 day moving average of $22.64.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PRVA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a research note on Tuesday, September 29th. Canaccord Genuity Group upped their target price on shares of Privia Health Group from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Friday. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler lifted their target price on Privia Health Group from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.25.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia reported Q3 earnings of $0.21 per share, above the $0.09 consensus estimate, and revenue of $656.96 million versus expectations of $610.72 million. Revenue rose 13.2% year over year. Privia Health Q3 results
• Positive Sentiment: The company raised full-year 2026 guidance across all key financial metrics. Year-to-date adjusted EBITDA was $114.7 million, up 21.9% from the same period in 2025, supporting the improved outlook. Privia Health Q3 results
• Positive Sentiment: Canaccord Genuity raised its price target from $32 to $33 and maintained a Buy rating. Piper Sandler raised its target from $36 to $38 and kept an Overweight rating, signaling increased analyst confidence. Canaccord Genuity price-target update Piper Sandler ratings
• Positive Sentiment: A valuation analysis argued that PRVA could be undervalued following its earnings beat, adding to the positive post-results narrative. Privia Health valuation analysis
• Negative Sentiment: Despite beating estimates, reported quarterly EPS of $0.21 was below the $0.29 reported a year earlier, a potential caveat for investors weighing the strong revenue growth and raised guidance.

Privia Health Group Company Profile

Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.

Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.